摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Pregn-4-en-3-one, 11,17,20,21-tetrahydroxy- | 489459-28-1

中文名称
——
中文别名
——
英文名称
Pregn-4-en-3-one, 11,17,20,21-tetrahydroxy-
英文别名
(8S,9S,10R,13S,14S,17R)-17-(1,2-dihydroxyethyl)-11,17-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
Pregn-4-en-3-one, 11,17,20,21-tetrahydroxy-化学式
CAS
489459-28-1
化学式
C21H32O5
mdl
——
分子量
364.5
InChiKey
AWWCEQOCFFQUKS-HQHHDLLGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    98
  • 氢给体数:
    4
  • 氢受体数:
    5

文献信息

  • HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
    申请人:Ripple Therapeutics Corporation
    公开号:US20210347809A1
    公开(公告)日:2021-11-11
    Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.
    本文描述了可加工的组合物,其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法,包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑肿、后部炎症、前部炎症、黄斑变性(如湿性黄斑变性(AMD)或干性AMD)、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力(IOP)和/或其他理想活性的类固醇前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
  • Neuroactive steroid formulations and methods of treating CNS disorders
    申请人:Sage Therapeutics, Inc.
    公开号:US10322139B2
    公开(公告)日:2019-06-18
    Formulations of comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., a β-cyclodextrin, e.g., a sulfo butyl ether β-cyclodextrin, e.g., CAPTISOL®; and methods of use in treating CNS disorders.
    该配方包括一种神经活性类固醇,例如,孕酮醇;以及可选的环糊精,例如β-环糊精,例如磺酸丁基醚β-环糊精,例如β-环糊精,例如磺酸丁基醚β-环糊精,例如CAPTISOL®;以及在治疗中枢神经系统疾病方面的使用方法。
  • Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine mediated toxicity
    申请人:THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
    公开号:EP1741779A2
    公开(公告)日:2007-01-10
    The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.
    本发明涉及抑制迁移抑制因子(MIF)释放和/或其生物活性的组合物和方法。 特别是,本发明涉及将此类组合物和方法用于治疗涉及细胞因子介导的毒性的各种病症,其中包括但不限于休克、炎症、移植物抗宿主疾病和/或自身免疫性疾病。
  • PREPARATION OF A COMPOSITION COMPRISING ALLOPREGNANOLONE AND SULFOBUTYLETHER-BETA-CYCLODEXTRIN
    申请人:Sage Therapeutics, Inc.
    公开号:EP3957309A1
    公开(公告)日:2022-02-23
    Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.
    本文描述的是治疗癫痫或癫痫状态的方法,例如,抽搐性癫痫状态,例如,早期癫痫状态,建立性癫痫状态,难治性癫痫状态,超级难治性癫痫状态,例如,超级难治性全身性癫痫状态;非抽搐性癫痫状态,例如、全身性周期性癫痫样放电;周期性侧向癫痫样放电;癫痫发作,如急性重复性癫痫发作、群集性癫痫发作,该方法包括向受试者施用神经活性类固醇
  • Processes and host cells for genome, pathway, and biomolecular engineering
    申请人:enEvolv, Inc.
    公开号:US10370654B2
    公开(公告)日:2019-08-06
    The present disclosure provides compositions and methods for genomic engineering.
    本公开提供了基因组工程的组合物和方法。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B